The U.S. Food and Drug Administration (FDA) has announced that the supply shortages of Eli Lilly's (LLY, Financial) popular weight-loss and diabetes medications, Zepbound and Mounjaro, have been re...

The U.S. Food and Drug Administration (FDA) recently announced that the shortage of Eli Lilly's weight loss medications, Mounjaro and Zepbound, has been resolved. While these drugs, which contain t...

CNBC's Angelica Peebles joins 'Squawk Box' with the latest news.

U.S. drugmaker Eli Lilly said on Wednesday it will invest $4.5 billion to create a new center for advanced manufacturing and drug development in Indiana.

Eli Lilly is making massive investments in manufacturing -- a key challenge now. The point of those investments is to produce enough of its drugs to meet demand.

Eli Lilly and Novo Nordisk are spending billions to find new cardiometabolic drugs. Both companies are interested in the possibilities of genetic medicines.

Eli Lilly is pretty close to a $1 trillion valuation. Its lineup and pipeline will support strong growth through 2030.

Certain economic sectors tend to be more resilient in an uncertain macroeconomic climate. Pharmaceutical giant Eli Lilly owns a portfolio of mainstay and emerging blockbuster drugs.

Eli Lilly's two weight loss drugs have become blockbusters, bringing in more than $1 billion in annual revenue. Demand is growing in this market, but so is competition.

Japan is the second major market where LLY's Kisunla has been approved. The drug was first approved in the United States in July 2024.

Monthly EGBLYSS maintenance dosing sustained clear or almost-clear skin for up to three years in the vast majority of ADvocate 1 and 2 responders Nearly 87 percent of patients taking EBGLYSS did no...

Japan, with its rapidly aging population, is expected to have more than 5 million patients with dementia by 2030. Alzheimer's is the most common form of dementia, accounting for more than 67% of ca...

Eli Lilly said on Tuesday Japan's health ministry has approved donanemab, its drug for Alzheimer's disease, providing patients with another treatment option after Eisai and Biogen's Leqembi receive...

Since ChatGPT was released almost two years ago, shares of Nvidia have soared over 500%. Outside of the tech sector, new diabetes and obesity treatments have revved up the pharma space.

Eli Lilly's long-term growth prospects have been secured by the improved supply in H2'24 and the incoming capacity additions from H1'25 onwards. This is on top of the introduction of its D2C channe...